Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China - Concepedia

Concepedia

Publication | Open Access

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

DOI Full Paper Access

19

Citations

26

References

2021

Year

Jinhong Gong, Qian Wan, Jingjing Shang, Xiaodan Qian, Dan Su, Zhiqiang Sun, Guangjun Liu

Advances in Therapy

Further-line TreatmentCost-effectiveness AnalysisMedicineCancer ManagementBronchial NeoplasmImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung Cancer

References

	Year	Citations

Page 1

Page 1